博瑞医药，筹划H股上市

Group 1 - The company announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy and overseas business layout [1] - The funds raised from the H-share issuance will be used for R&D activities, expanding production lines, strategic investments and acquisitions, and general corporate purposes [1] - The company appointed Ernst & Young as the auditing firm for the H-share issuance [1] Group 2 - In the first half of 2025, the company reported revenue of 537 million yuan, a year-on-year decrease of 18.28%, and a net profit attributable to shareholders of 17.17 million yuan, down 83.85% [2] - The company's R&D expenditure as a percentage of revenue increased by 43.12 percentage points compared to the same period last year, driven by a focus on R&D for GLP-1 innovative drugs and inhalation formulations [2] - The company plans to raise up to 500 million yuan through a private placement, with the actual controller subscribing at a price of 22.56 yuan per share [2]